Back

The impact of right ventricular size and function on long-term outcomes in patients undergoing cardiac resynchronization therapy

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure: let’s re-synchronise please Cardiac Resynchronisation Therapy (CRT) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Xavier Galloo

University Hospital (UZ) Brussels, Brussels (Belgium)

5 More presentations in this session

Presentation thumbnail
Cardiac resynchronisation therapy and implantable cardioverter-defibrillator in non-ischaemic systolic heart failure: extended follow-up of the DANISH trial
Doctor A. Yafasova (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Cardiac resynchronization therapy: association between genetically determinated dilated cardiomyopathy and dissinchronopathy
Doctor M. Zecchin (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac resynchronisation therapy in patients with cardiac sarcoidosis
Doctor R. Ahmed (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Biventricular or left univentricular pacing in heart failure patients: is there a better strategy
Doctor M. Barradas (Ponta Delgada, PT)
Abstract Slides Video
Presentation thumbnail
Prediction of response to cardiac resynchronization therapy using cardiac magnetic resonance imaging in non-ischemic dilated cardiomyopathy
Doctor S. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: let’s re-synchronise please

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Impact of right ventricular dimension and function on outcomes in patients undergoing cardiac resynchronization therapy
thumbnail
Congress Presentation
The impact of baseline right heart size and function on heart failure hospitalization and mortality: 2-year results of the TRILUMINATE Trial
thumbnail
Congress Presentation
Right ventricular systolic pressure is an independent risk factor of all-cause death and inappropriate therapies in patients with implanted CRT-D

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources